Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure ...
Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback